OBJECTIVE: To probe into the efficacy of Fuzheng Jiedu Kang’ai prescription in the treatment of advanced non-small cell lung cancer（ NSCLC） and its effects on bone marrow suppression after chemotherapy.METHODS: Totally 100 patients with NSCLC admitted into Chuzhou the First People’s Hospital from Jan. 2016 to Mar. 2019 were extracted to be divided into the control group and the study group via the random number table

with50 cases in each group. The control group was treated with conventional chemotherapy

while the study group received Fuzheng Jiedu Kang’ai prescription on the basis of the control group. Two groups were treated continuously for 2 cycles of chemotherapy. The clinical efficacy

white blood cell count

platelet count and hemoglobin count before and after treatment were recorded

differences of incidence of bone marrow suppression and Karnofsky（ KPS） score of two groups were compared. RESULTS: The total effective rate of the study group was 62. 00%（ 31/50）

significantly higher than 36. 00%（ 18/50） of the control group

the difference was statistically significant（ P < 0. 05）. After treatment

the white blood cell count

platelet count and hemoglobin count of two groups were significantly lower than those before treatment

yet the study group was significantly higher than the control group

with statistically significant differences（ P < 0. 05）. The incidence of bone marrow suppression in the study group was 38. 00%（ 19/50）

significantly lower than 68. 00%（ 34/50） in the control group

and the difference was statistically significant（ P <0. 05）. After treatment

the improvement rate and stability rate of KPS score in the study group [34. 00%（ 17/50）and 46. 00%（ 23/50） ] were significantly better than those in the control group [14. 00%（ 7/50） and 16. 00%（ 8/50） ]

with statistically significant differences（ P<0. 05）. CONCLUSIONS: The efficacy of Fuzheng Jiedu Kang’ai prescription in the treatment of NSCLC is significant

which can reduce bone marrow suppression in patients after chemotherapy and improve patients’ quality of life.